Ketamine (2-(2-chlorophenyl)-(1-methylamino)-cyclohexanone) is a rapid-acting dissociative general anaesthetic whose hallucinogenic properties have made it a popular drug of abuse. Ketamine comprises two optical isomers, with differing pharmacology. In the present study, the effects of (+)- and (−)-ketamine on stimulated efflux and reuptake of dopamine (DA), noradrenaline (NA) and serotonin (5-HT) were compared in isolated superfused slices of the rat caudatoputamen (CPu), ventral bed nucleus of the stria terminalis (BSTV) or dorsal raphe nucleus (DRN), respectively. Monoamine efflux was elicited by local electrical stimulation (20 pulses, 100Hz trains) at tungsten microelectrodes and measured at adjacent carbon fibre microelectrodes using fast cyclic voltammetry (FCV). In CPu (+)-ketamine increased stimulated DA efflux and slowed DA reuptake in a concentration-dependent manner (25–200μM). At 100μM (+)-ketamine increased DA efflux by 109±20% (mean±S.E.M., n=13) of control values after 30min (P<0.001 versus control) and prolonged uptake half-time (t1/2) by 76±38% (n=9, P<0.001) of control. In contrast (−)-ketamine (100μM) had no effect on DA efflux or uptake. In DRN, both isomers (100μM) increased stimulated 5-HT efflux. (−)-Ketamine had a larger effect (P<0.001), an 88±15% increase in 5-HT efflux (n=9) versus 46±10% (n=8) for the (+)-isomer. The isomers had similar effects on 5-HT uptake, increasing t1/2 by approximately 200%. No evidence of stereospecificity was seen in BSTV: both isomers had small effects (+)- and (−)-ketamine (100μM) increasing NA efflux by 43±10% (n=7, P<0.001) and 29±8% (n=7, P<0.001), respectively. The isomers also had identical effects on NA uptake, each increasing uptake t1/2 by approximately 100%. In summary, our data show that the optical isomers of ketamine have strikingly different stereospecificity for the monoamine systems and one might predict, therefore, a different psychotomimetic potential.

Radiolabelling of brain tissue has long been used to facilitate detection of transmitter efflux, on the assumption that egress of tritiated monoamines reflects that of the endogenous transmitter. The present study tested the hypothesis that the application of exogenous serotonin (5-HT) to mesencephalic slices, in the manner used during a typical radiolabelling protocol, leads to efflux of 5-HT from physiologically inappropriate loci such as other non-serotonergic neurones. We used fast cyclic voltammetry (FCV) to determine the effect of tissue pre-incubation with 5-HT on electrically-stimulated 5-HT efflux and reuptake in rat mesencephalic slices. Seven subregions were studied, including the dorsal raphe nucleus (DRN), dorsomedial periaqueductal grey (PAGdm) and the oral part of the pontine reticular nucleus (PnO). In control slices (pre-incubated without 5-HT), stimulated 5-HT efflux was only detectable in DRN, PAGdm and occasionally in PnO. In slices incubated in 5-HT (100nM) for 30min, stimulated 5-HT efflux was detected in all seven subregions studied. In such slices, citalopram (75nM) increased efflux and reuptake t1/2 in DRN to 201±21 and 487±117% of pre-drug values (P<0.05) but had no significant effect on either measure in PnO. The 5-HT1 autoreceptor agonist, 5-carboxamidotryptamine (5-CT, 100nM) decreased efflux in DRN by 54±6% (P<0.05), but was without effect (10±14%) in PnO. The present results show that pre-incubation in 5-HT allows stimulated 5-HT efflux from regions of the mesencephalon other than DRN and PAGdm. This stimulated 5-HT efflux is apparently not influenced by 5-HT transporters or 5-HT1 autoreceptors, suggesting that efflux is ectopic, an artefact of the pre-incubation process. In summary, incubation of rat mesencephalic tissue in 5-HT, in the manner of a typical radiolabelling protocol, results in stimulated 5-HT efflux from non-physiological sites. The results of such transmitter efflux studies should thus be interpreted with caution.

In this study, we investigated which subtype(s) of alpha(2)-adrenoceptor control stimulated noradrenaline (NA) release and noradrenergic cell firing in the locus coeruleus (LC) of monoamine oxidase-A knockout (MAO-A KO) and C3H/HeJ wildtype mice. On short stimulus trains (10 pulses, 200 Hz), the alpha(2) agonist dexmedetomidine (10 nm) reduced NA efflux by 78 +/- 8% and 51 +/- 8% in wildtype and MAO-A KO mice, respectively. In both strains, BRL 44408 (100 nm) and ARC 239 (100 nm) each partially blocked the effect of dexmedetomidine. In MAO-A KO mice, BRL 44408 (100 nm) increased evoked NA efflux on short trains while ARC 239 (100 nm) had no effect. The two antagonists in combination increased NA efflux (by 81 +/- 34%, P < 0.001), significantly more than by BRL 44408 alone. Conversely, in wildtype mice, the alpha2-adrenoceptor antagonists did not significantly increase LC NA efflux. On long stimuli (30 pulses, 10 Hz), NA efflux was increased by BRL 44408 (P < 0.001) but not by ARC 239. The effect of BRL 44408 was significantly greater in MAO-A KO than wildtype mice (208 +/- 43% vs. 113 +/- 31% increase, P < 0.001). When we examined noradrenergic cell firing, we found that dexmedetomidine inhibited LC cell firing in both strains with comparable EC(50) values (2-5 nm), although E(max) was significantly lower in MAO-A KO mice (P < 0.001). The agonist effect was antagonized by BRL 44408 (P < 0.001) in wildtype but not in MAO-A KO mice, with a pK(B) of 7.75. ARC 239 had no effect on the agonist response in either strain. A combination of the antagonists was no more effective than BRL 44408 alone (in wildtypes) and had no effect in MAO-A KO mice. Neither BRL 44408 nor ARC 239 affected basal LC cell firing in wildtype or MAO-A KO mice. Collectively, these results suggest that, analogous to other monoamine cell groups, there are differences in the autoreceptor populations controlling NA efflux and LC cell firing and that important differences exist between MAO-A KO and wildtype mice.

Brain injury is the leading cause of death in trauma patients and produces a large amount of disability. Unfortunately, it is particularly prevalent in young adults, with all the suffering and socio-economic loss this implies. It has a complex neurobiology that has been elucidated largely in animal models, but it has been more difficult to apply the knowledge gained to man, partly due to the heterogeneous nature of human brain injuries.

Previous studies using a rat brain slice model of cerebral 'ischaemia' (hypoxia and hypoglycaemia) have suggested that volatile anaesthetics may have cerebroprotective potential. In this study, we tested the cerebroprotective profile of four volatile anaesthetics in this model by two independent means: voltammetric measurement of 'ischaemia'-induced dopamine (DA) release and post-'ischaemic' tissue staining with 2,3,5-triphenyltetrazolium chloride (TTC). 'Ischaemia' caused a characteristic pattern of DA release. Halothane, isoflurane and enflurane did not affect the time from onset of 'ischaemia' to the initiation of DA release. However, all three volatile agents significantly increased (P<0.01, P<0.05, P<0.001, respectively) the time taken for 'ischaemia'-induced DA release to reach maximum and reduced the rate of DA release. Enflurane, unlike halothane or isoflurane, reduced the maximal extracellular DA concentration induced by 'ischaemia' (P<0.01). The effects of sevoflurane were inconsistent. At the higher concentrations used, the volatile anaesthetics frequently changed the character of DA release from monophasic to biphasic, an effect only previously seen in this model with Na(+) channel blockers. 'Ischaemia' also diminished the subsequent level of tissue staining with TTC. When the effects of the volatile agents were analysed by TTC staining, only enflurane showed any cerebroprotective effects and these were limited to the striatum (P<0.01). High concentrations of halothane, isoflurane and enflurane appeared to have some 'toxic' effects, reducing TTC staining in control slices. In summary, we do not find any consistent evidence that volatile anaesthetics are cerebroprotective in this model.

Monoamine oxidase-A knockout (MAO-A KO) mice have elevated brain serotonin (5-HT) and noradrenaline (NA) levels, and one would therefore anticipate increased monoamine release and compensatory changes in other aspects of presynaptic monoamine function. In this study we used voltammetry in brain slices from the locus coeruleus (LC), dorsal raphe (DRN) and striatum (CPu) in 7-week-old MAO-A KO and C3H control mice to measure stimulated monoamine efflux and its control by amine transporters and autoreceptors. In LC, peak NA efflux on stimulation (99 pulses, 100 Hz) was higher in MAO-A KO than C3H mice (938 +/- 58 nm cf. 511 +/- 42 nm; P < 0.001). The NA uptake half time (t(1/2)) was longer in MAO-A KO than in C3H mice (6.0 +/- 0.9 s cf. 1.9 +/- 0.3 s; P < 0.001) and the selective NA reuptake inhibitor desipramine (50 nm) had a smaller effect in MAO-A KO mice. NA transporter binding was significantly lower in the LC of MAO-A KO mice compared to C3H controls (P < 0.01) but not in the DRN. The alpha 2 agonist dexmedetomidine (10 nm) decreased stimulated NA efflux more in C3H than in MAO-A KO mice (73.3% cf. 29.6% inhibition, P < 0.001). In DRN, peak 5-HT efflux on stimulation (99 pulses, 100 Hz) was greater (P < 0.01) in MAO-A KO (262 +/- 44 nm) than C3H mice (157 +/- 16 nm). Moreover, 5-HT uptake t(1/2) was longer (P < 0.05) in MAO-A KO than in C3H mice (8.8 +/- 1.1 s cf. 4.9 +/- 0.6 s, P < 0.05) and the effect of citalopram (75 nm) was attenuated in MAO-A KOs. Serotonin transporter binding was also lower in both the DRN and LC of MAO-A KO mice. The 5-HT(1A) agonist 8-OH-DPAT (1 microm) decreased 5-HT efflux more in C3H than in MAO-A KO mice (38.3% inhibition cf. 21.6%, P < 0.001). In contrast, there were no significant differences between MAO-A KO and C3H mice in CPu dopamine efflux and uptake and the effect of the D(2/3) agonist quinpirole was similar in the two strains. In summary, MAO-A KO mice show major dysregulation of monoaminergic presynaptic mechanisms such as autoreceptor control and transporter kinetics.

Ketamine (2-o-chlorophenenyl-2-methylaminocyclohexanone hydrochloride) is a dissociative general anaesthetic with neuroprotective properties. Since ketamine is optically active, we compared the neuroprotective efficacy of the (+)- or (−)-enantiomers in global cerebral ischaemia. Rat corticostriatal slices superfused with, or incubated in, artificial CSF at 34°C were subjected to a brief ischaemic insult. Dopamine efflux was measured using fast cyclic voltammetry. Tissue metabolism was determined with 2,3,5-triphenyltetrazolium chloride staining, a marker of mitochondrial enzyme activity. In control slices, ischaemia caused rapid striatal dopamine release (to 122 μM over 18 s) after an initial delay of 149s. Racemic ketamine (100 μmol/l) significantly delayed (by 24%, P<0.05), slowed (by 63%, P<0.01) and reduced (by 27%, P<0.05) ischaemia-induced dopamine release. Ischaemia (10 min) also caused significant decreases in striatal (25%, P<0.01) and cortical (31%, P<0.001) metabolic activity, manifested as a drop in mean TTC staining intensity. Racemic ketamine and its (+)- and (−)-enantiomers (each 100 μM) attenuated the loss of metabolic activity in the striatum. However, in the cortex, only (+)-ketamine (100 μM) was significantly neuroprotective. We conclude that neuroprotection by ketamine in cerebral ischaemia is both region- and isomer-dependent.

The atypical analgesic tramadol has strong structural similarities to the antidepressant venlafaxine and is a mixed noradrenaline (NA) and serotonin (5-HT) uptake inhibitor. Because tramadol has been found active in the forced swim test, a common predictor of antidepressant efficacy, we therefore examined the effects of chronic tramadol on various pre- and post-synaptic monoamine measures. Male Wistar rats (150–200 g) received tramadol (20 mg/kg i.p.) or vehicle for 21 days and were sacrificed 24 h after the last dose. Quantitative autoradiography revealed that specific frontocortical [3H]dihydroalprenolol and [3H]ketanserin binding was lower in the chronic tramadol group than controls (β: 37 ± 8 and 217 ± 56 fmol/mg; 5-HT2A: 23 ± 3 and 44 ± 7 fmol/mg, respectively, p < 0.05). Chronic tramadol had no effect on the magnitude of electrically stimulated noradrenaline (NA) efflux or uptake in locus coeruleus (LC) slices. Although dexmedetomidine (10 nM) decreased LC NA efflux equally (by approximately 60%) in chronic tramadol and vehicle groups, desipramine (50 nM) increased LC NA efflux more in vehicle (to 164 ± 7%) than tramadol-treated rats (144 ± 6%; p< 0.05). Chronic tramadol had no effect on dorsal raphé (DRN) or median raphé (MRN) 5-HT efflux. However, 5-HT uptake in tramadol-treated rats was slower (p < 0.05) in MRN and nearly so (p= 0.055) in DRN. The selective 5-HT1Aagonist 8-OH-DPAT reduced 5-HT efflux in both DRN and MRN. Its effect in DRN was greater in rats given chronic tramadol than in vehicle controls (54 ± 2 versus 32 ± 6% reduction in 5-HT efflux, respectively). In conclusion, we suggest that tramadol has many of the pre and postsynaptic neurochemical features of a conventional antidepressant, as might be predicted from its pharmacology.

Polymorphisms in the regulatory region of the human apolipoprotein E gene (gene, APOE; protein, apoE) have been implicated in Alzheimer's disease. Here we describe in detail the advantages of a simple method for haplotype analysis of this region (at -491 and -427 bases relative to the transcription start site of the gene). The promoter region of the APOE gene was amplified by polymerase chain reaction (PCR) and this fragment was then used as a template for PCR with "nested" primers to generate a 228-bp product incorporating both the -491 and the -427 loci. PCR products were then digested with DraI and AluI together and subjected to polyacrylamide gel electrophoresis. The distinct pattern of bands appearing on the gel was then used to ascribe [-491,-427] haplotypes to each subject, from which -491 and -427 genotypes were inferred. -491 and -427 genotypes were also confirmed by digestion with DraI alone or AluI alone. Haplotype analysis was successful in all 20 samples analyzed and was 100% consistent with genotyping. We suggest that this is a reliable, time-saving method that the will be useful in large-scale APOE promoter genotyping studies.

In the present studies we have examined the effects of a new calcium channel blocker, LY393615 ((N-Butyl-[5,5-bis-(4-fluorophenyl)tetrahydrofuran-2-yl]methylamine hydrochloride, NCC1048) in a model of hypoxia-hypoglycaemia in vitro and in a gerbil model of global and in two rat models of focal cerebral ischaemia in vivo. Results indicated that LY393615 protected against hypoxia-hypoglycaemic insults in brain slices and also provided significant protection against ischaemia-induced hippocampal damage in gerbil global cerebral ischaemia when dosed at 10, 12.5 (P<0.05) or 15 mg/kg i.p. (P<0.01) 30 min before and 2 h 30 min after occlusion. The compound penetrated the brain well after a 15 mg/kg i.p. dose and had a half-life of 2.5 h. In further studies LY393615 was protective 1 h post-occlusion when administered at 15 mg/kg i.p. followed by 2 doses of 5 mg/kg i.p. 2 and 3 h later. LY393615 dosed at 15 mg/kg i.p. followed by 2 further doses of 5 mg/kg i.p. (2 and 3 h later) also produced a significant reduction in the infarct volume following Endothelin-1 (Et-1) middle cerebral artery occlusion in the rat when administration was initiated immediately (P<0.01) or 1 h (P<0.05) after occlusion. The compound was also evaluated in the intraluminal monofilament model of focal ischaemia. The animals had the middle cerebral artery occluded for 2 h, and 15 min after reperfusion LY393615 was administered at 15 mg/kg i.p. followed by 2 mg/kg/h i.v. infusion for 6 h. There was no reduction in infarct volume using this dosing protocol. In conclusion, in the present studies we have reported that a novel calcium channel blocker, LY393615, with good bioavailability protects against neuronal damage caused by hypoxia-hypoglycaemia in vitro and both global and focal cerebral ischaemia in vivo. The compound is neuroprotective when administered post-occlusion and may therefore be a useful anti-ischaemic agent.

Release of excitatory amino acids and dopamine plays a central role in neuronal damage after cerebral ischaemia. In the present study, we used an in vitro model of ischaemia to investigate the effects of sevoflurane on dopamine, glutamate and aspartate efflux from rat corticostriatal slices. Slices were superfused with artificial cerebrospinal fluid at 34 degrees C and episodes of 'ischaemia' were mimicked by removal of oxygen and reduction in glucose concentration from 4 to 2 mmol litre(-1) for < or = 30 min. Dopamine efflux was monitored in situ by voltammetry while glutamate and aspartate concentrations in samples of the superfusate were measured by HPLC with fluorescence detection. Neurotransmitter outflow from slices was measured in the absence or presence of sevoflurane (4%). After induction of ischaemia in control slices, there was a mean (SEM) delay of 166 (7) s (n = 5) before sudden efflux of dopamine which reached a maximum extracellular concentration of 77.0 (15.2) micromol litre(-1). Sevoflurane (4%) reduced the rate of dopamine efflux during ischaemia (6.90 (1.5) and 4.73 (1.76) micromol litre(-1) s(-1) in controls and sevoflurane-treated slices, respectively; P<0.05), without affecting its onset or magnitude. Excitatory amino acid efflux was much slower. lschaemia-induced glutamate efflux had not reached maximum after 30 min of ischaemia. Basal (pre-ischaemic) glutamate and aspartate efflux per slice was 94.8 (24.8) and 69.3 (31.5) nmol litre(-1) superfusate (n = 4) and was not significantly reduced by 4% sevoflurane. lschaemia greatly increased glutamate and aspartate efflux (to a maximum of 919 (244)% and 974 (489)% of control, respectively). However, ischaemia-induced efflux of both glutamate and aspartate was significantly reduced by 4% sevoflurane (P < 0.001 for glutamate, P < 0.01 for aspartate). In summary, sevoflurane may owe part of its reported neuroprotective effect to a reduction of ischaemia-induced efflux of excitatory amino acids and, to a lesser extent, dopamine.

2,3,5-Triphenyltetrazolium chloride (TTC), a marker of mitochondrial enzyme activity, is widely used to assess the effects of cerebral ischaemia in vivo. In the present study, we characterised its utility as a simple rapid macrohistological measure of ischaemic damage in brain slices. Coronal rat corticostriatal slices were incubated in oxygenated artificial cerebrospinal fluid (aCSF) until subjected to 'ischaemia' (deoxygenated, hypoglycaemic aCSF) for up to 12 min. After a further 30 min to 16 h of reincubation in oxygenated aCSF, slices were stained with TTC, fixed with formalin and transferred to cover slips. The slices were scanned in 8-bit greyscale using a standard desktop scanner and the staining analysed by densitometry of the acquired images. Control slices stained a rich pink/red. Ischaemia (10 min) reduced both the area and intensity of staining. Both measures of striatal staining were negatively correlated with the duration of ischaemia (0-12 min). Furthermore, staining in the striatum correlated significantly with cortical TTC staining. The effects of TTC concentration (0.063-0.5% w/v) and post-ischaemic interval (30 min to 16 h) were examined upon the intensity of TTC staining. (+)-MK 801 prevented the ischaemia-induced reduction in TTC staining, consistent with cerebroprotection. These data suggest that TTC staining of brain slices may be used to quantify ischaemic injury and cerebroprotection.

The serotonergic cells of the dorsal raphé nucleus innervate much of the forebrain and are thought to be involved in the mechanism of action of antidepressants. Dysfunction of these cells might be involved in the neural mechanisms underlying depression and suicide. The traffic in pathways emanating from the dorsal raphé nucleus is controlled by 5-HT(1) autoreceptors. Until recently it was thought that the autoreceptors in the dorsal raphé nucleus were solely of the 5-HT(1A) subtype. In this article, we discuss evidence that the situation is more complex and that multiple 5-HT(1) subtypes govern different aspects of 5-HT function in the dorsal raphé nucleus presenting new therapeutic opportunities.